Summary.-The inhibitory effect of an i.v. or i.p. injection of C. parvum on intrastrain transplants of a mammary carcinoma in A/HeJ mice has been confirmed, and it has been shown further that C. parvum inhibits the growth of transplants of sarcomata induced with methylcholanthrene both in this strain (members of which lack the fifth component of complement) and in CBA mice (which are not complement deficient). In experiments with the mammary carcinoma, 2 injections of C. parvum on days + 3 and + 9 were more effective than a single injection on day + 3; injections on days + 3 and + 6, or + 3 and + 12, appeared to be marginally less effective than on days + 3 and + 9, but the difference was not statistically significant.
As already reported, the growth of intrastrain transplants of a mammary carcinoma in A-strain mice may be inhibited to a moderate extent by treating the recipient with a single intravenous or intraperitoneal injection of an appropriate strain of C. parvum (Woodruff and Boak, 1966; Smith and Woodruff, 1968; Woodruff and Inchley, 1971a) or by incubating the tumour cells prior to inoculation with heterospecific antitumour globulin (ATG) (Woodruff and Smith, 1970) . Significantly greater inhibition may be obtained by combining these procedures (Woodruff and Inchley, 197 
la).
The experiments now reported extend this work in two directions. In the first place we have studied the effect of treating the animal with ATG, either alone or in combination with C. parvum. Secondly, in order to determine whether or not the results obtained previously were peculiar to the particular model chosen, in which the tumour was of viral 6 origin and the mice lacked the fifth component of complement (C5), we have set up similar experiments with 2 fibrosarcomata induced with methylcholanthrene, one in A/HeJ mice (i.e. the strain used in previous work with the mammary carcinoma) and one in CBA mice, which possess all components of the complement system.
MATERIALS AND METHODS
Six experiments were performed, 2 with A/HeJ mammary carcinomata, 2 with a fibrosarcoma induced in A/HeJ mice with methyleholanthrene and 2 with a fibrosarcoma induced in CBA mice by the same carcinogen. The detailed protocols are shown in Tables I, II and III. It should be noted that in these experiments C. parvum was injected on day + 3 (i.e. 3 days after tumour inoculation) and not on day -2 as previously.
Mice. .2; (Woodruff and Inchley, 1971a) .
ATG.-ATG (A/HeJ-Ca) was prepared by salt precipitation and batch chromatography from the serum of rabbits immunized with a mixture of tumour cells prepared with pronase from several different A/HeJ mammary tumours according to the schedule described previously (Woodruff and Inchley, 1971a) .
ATG (A/HeJ-Sa) and ATG (CBA-Sa) were prepared similarly from the serum of rabbits immunized in the same manner with cells prepared with pronase from transplants of one or other of the fibrosarcomata used in the experiments. The cytotoxic titres-1 of these preparations by the techniques previously described EFFECT OF C. PARVUM AND ANTI-TUMOUR GLOBULIN ON MOUSE TUMOURS 71 (Woodruff and Smith, 1970) , using guinea-pig C and taking 50% cell death as the end point, were 64, 32 and 64 respectively. Normal rabbit IgG (NRG) was prepared from the pooled serum of normal rabbits. Pre-incubation of tumour cells.-2. 107 cells were incubated in 2-6 ml Dulbecco's solution containing 6-5 mg of the corresponding ATG for 60 min at 370C without added complement.
RESULTS
The results are shown in the tables and figures. They may be summarized as follows:
A/HeJ mammary carcinoma
In the first experiment (Table I ; Fig. 1 In the first experiment (Table III ; Fig. 4 ) growth of the tumour was inhibited to about the same extent by pre-incubation of the cells with ATG or by a single i.p. injection of C. parvum. Pre-incubation of the tumour cells with ATG combined with injection of C. parvum was still more effective. Intravenous injection of C. parvum seemed initially to be more effective than i.p. injection but after a few weeks the difference was no longer apparent.
In the second experiment (Table III ; Fig. 5 ) the inhibitory effect of C. parvum was confirmed, but i.p. injection was no less effective than i.v. As in the experi- 
DISCUSSION
It seems clear that the inhibitory effect of C. parvum is not peculiar to the model previously investigated but extends to intra-strain transplants of chemically induced sarcomata in both complement (C5) deficient and non-complement deficient mice. The effect of C. parvum on cholanthrene-induced sarcomata in CBA mice has also been studied by Currie and Bagshawe (1970) . The inhibition of tumour growth in animals treated with C. parvum alone appears to have been weak in comparison with that obtained in the present experiment, probably because of differen- ces in the strain of organism and in the method of preparing the vaccine, which was heat-killed (as against formalinkilled). It is noteworthy, however, that despite this, Currie and Bagshawe observed a marked synergistic effect when a single injection of C. parvum was preceded by a course of injections of cyclophosphamide.
The effect of pre-incubating the tumour cells in the present experiments with heterospecific ATG was variable, inhibition of growth being greatest with the (CBA sarcoma but clearly demonstrable also with the A-strain mammarv carcinoma. The synergistic effect of combining pre-incubation of the cells and injection of C. parvumr, which was so marked in previous experiments with the A-strain mammary carcinoma, was less striking in the present experiment with this tumour, possibly because of the different timing of the C. parvum injection, but was quite dramatic with the CBA/H sarcoma.
The observation that i.v. injection of ATG did not inhibit the growth of any of the tumours studied is in line with the experience of other investigators (see Motta, 1971 , for review), who have found that, with a few exceptions, treatment with antiserum is ineffective with mouse tumours other than leukoses.
In discussing possible reasons for the failure of passive immunotherapy it is convenient to begin by considering the factors which determine the susceptibility of cells to destruction consequent on exposure to antibody and complement. These include intrinsic properties of the cells, the specificity and class of antibody, the availability of necessary complement components, and the milieu in which the reaction occurs.
In the case of lysis of both normal and neoplastic nucleated cells by isoantibody in vitro, the concentration and distribution of corresponding antigenic determinants on the surface of the cell are of crucial importance (Moller and M6ller, 1962; Winn, 1965) , though other properties of the cell, such as the capacity to repair lesions resulting from activation of complement on the cell surface, may also be relevant. Lysis of nucleated cells by heterospecific antibody in vitro has not been extensively analysed, but it might be expected that the number of combining sites would be greater than with isoantibodies and in consequence less likely to be a limiting factor, and results obtained in this laboratory (Woodruff and Inchley, 197 lb) with one particular system are consistent with this suggestion. Whether or not this holds good generally, however, it seems clear that the failure of passive immunization in the present experiments cannot be attributed wholly to some intrinsic property of either the tumour cells or the antibody, since, when sensitized with the corresponding antibody, the cells of all the tumours were lysed in vitro by guinea-pig complement, and, as mentioned above, those of two of them 75 proved to be at a disadvantage as compared with normal cells when injected in vivo.
It seems likely that the explanation is to be found in the amount of antibody reaching the tumour cells under the conditions of the experiments, and on the availability of complement. To investigate this we are studying the uptake of radioactively labelled antibody by tumours in vivo and the complementary activity of serum from tumour bearing animals. Another approach is to try to prepare antibody which is more highly tumour specific, and therefore less liable to be mopped up by normal tissues, and to study the effect of injecting this alone or with exogenous complement.
Another possibility, which may also be tested by using sera which are more tumour specific, is that the ATG used in the present experiments exerted an immunosuppressive effect which was sufficient to counterbalance any damaging effect it had on the tumour.
Various agents which stimulate immunological responsiveness in a nonspecific way, including Bacillus Calmette Guerin (BCG) and synthetic polynucleotides, have been tried clinically in patients with acute lymphoblastic leukaemia by Mathe (Mathe et al., 1968; Mathe et al., 1970; Mathe, 1970) and some of the results have been encouraging. In our hands (Woodruff and Dunbar, unpublished) these have proved much less effective against mouse tumours than the preparation of C. parvum used in the present experiments. There would seem therefore to be a good case for undertaking a preliminary clinical trial of this preparation, either alone or in combination with chemotherapy or some other form of immunotherapy, in selected patients with residual cancer, provided that the criteria of uniformity and safety applicable to bacterial vaccines can be met.
